BeOne Medicines says Phase 3 HERIZON-GEA-01 data confirm TEVIMBRA + ZIIHERA benefit in HER2-positive gastroesophageal adenocarcinoma

BeOne Medicines announced data from its Phase 3 HERIZON-GEA-01 study confirming the benefits of TEVIMBRA plus ZIIHERA (zanidatamab-hrii) in treating patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma. Data presented at ESMO 2026 demonstrate sustained survival at three years in first-line HER2+ advanced gastroesophageal adenocarcinoma.

Detected & updated continuously · Source: Nebula